Method for predicting outcome of cancer in a subject
AssigneeTraslational Cancer Drugs Pharma, S.L.
InventorJuan Carlos Lacal Sanjuan
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for predicting the outcome of a subject suffering from cancer, based on the copy number of the CHKA gene in a sample from said subject. The invention also relates to a BAC composition and a method for detecting the number of copies of the CHKA gene.
Claims18
A composition comprising at least two polynucleotides selected from the group consisting of:
- (a) a polynucleotide comprising the human genomic fragment present in the CTD-2162L23 BAC (SEQ ID NO:1) or a variant thereof which hybridizes under stringent conditions to said polynucleotide,
- (b) a polynucleotide comprising the human genomic fragment present in the RP11-314K20 BAC (SEQ ID NO:2) or a variant thereof which hybridizes under stringent conditions to said polynucleotide,
- (c) a polynucleotide comprising the human genomic fragment present in the CTD-2655K5 BAC (SEQ ID NO:3) or a variant thereof which hybridizes under stringent conditions to said polynucleotide and
- (d) a polynucleotide comprising the human genomic fragment present in the CTC-783C1 BAC (SEQ ID NO:4) or a variant thereof which hybridizes under stringent conditions to said polynucleotide
- wherein said polynucleotides are not associated with all or a portion of a polynucleotide in which the isolated polynucleotide is found in nature.
4-6. (canceled)
An in vitro method for predicting the outcome of a subject suffering from cancer comprising detecting whether the CHKA gene is amplified in a sample from said subject, wherein amplification of the CHKA gene is indicative of an unfavourable outcome of the subject.
A method for determining the copy number of the CHKA gene which comprises:
- a. contacting a sample containing genetic material with a composition comprising at least two polynucleotides selected from the group consisting of:
- (i) a polynucleotide comprising the human genomic fragment present in the CTD-2162L23 BAC (SEQ ID NO:1) or a variant thereof which hybridizes under stringent conditions to said polynucleotide,
- (ii) a polynucleotide comprising the human genomic fragment present in the RP11-314K20 BAC (SEQ ID NO:2) or a variant thereof which hybridizes under stringent conditions to said polynucleotide,
- (iii) a polynucleotide comprising the human genomic fragment present in the CTD-2655K5 BAC (SEQ ID NO:3) or a variant thereof which hybridizes under stringent conditions to said polynucleotide and
- (iv) a polynucleotide comprising the human genomic fragment present in the CTC-783C1 BAC (SEQ ID NO:4) or a variant thereof which hybridizes under stringent conditions to said polynucleotide
- wherein said polynucleotides are not associated with all or a portion of a polynucleotide in which the isolated polynucleotide is found in nature wherein said contacting is carried out under conditions adequate for the hybridisation of the polynucleotides forming part of the composition with the CHKA gene or genes present in the sample;
- and
- b. determining the copy number of the CHKA gene based on the hybridisation of the composition with the sample containing genetic material.
Dependencies are inferred from the claim text.